Table 4 The relationship between the expression of STEAP2 and clinicopathological features of NSCLC patients
From: Expression and prognostic analyses of the significance of STEAP1 and STEAP2 in lung cancer
Pathological features | N | STEAP2 | χ2 | P | |
|---|---|---|---|---|---|
High expression | Low expression | ||||
n (%) | n (%) | ||||
Age | Â | Â | 0.198 | 0.656 | |
 ≤60 | 130 | 23 (17.7) | 107 (82.3) |  |  |
 >60 | 128 | 20 (15.6) | 108 (84.4) |  |  |
Sex | Â | Â | Â | 0.030 | 0.864 |
 Male | 159 | 27 (17.0) | 132 (83.0) |  |  |
 Female | 99 | 16 (16.2) | 83 (83.8) |  |  |
TNM clinical stages | Â | Â | Â | 19.379 | 0.000 |
 I and II stages | 108 | 31 (28.7) | 77 (71.3) |  |  |
 III and IV stages | 150 | 12 (8.0) | 138 (92.0) |  |  |
Histological type |  |  |  | 0.230※ | 0.891※ |
 Squamous carcinoma | 121 | 20 (16.5) | 101 (83.5) | 9.408# | 0.009# |
  I grade | 32 | 13 (40.6) | 19 (59.4) |  |  |
  II grade | 48 | 13 (27.1) | 35 (72.9) |  |  |
  III grade | 41 | 4 (9.8) | 37 (90.2) |  |  |
 Adenocarcinoma | 112 | 18 (16.1) | 94 (83.9) | 14.298* | 0.006* |
  Lepidic-predominant | 25 | 12 (48.0) | 13 (52.0) |  |  |
  Acinar-predominant | 21 | 9 (42.9) | 12 (57.1) |  |  |
  Papillary-predominant | 19 | 6 (31.6) | 13 (68.4) |  |  |
  Solid-predominant | 24 | 3 (12.5) | 21 (87.5) |  |  |
  Micropapillary-predominant | 23 | 2 (8.7) | 21(91.3) |  |  |
 Adenosquamous carcinoma | 25 | 5 (20.0) | 20 (80.0) |  |  |
Lymphatic metastasis | Â | Â | 35.352 | 0.000 | |
 N0 | 95 | 33 (34.7) | 62 (65.3) |  |  |
 N+ | 163 | 10 (6.1) | 153 (93.9) |  |  |